Loading organizations...
Based in Ghent, Belgium, Antelope Dx develops palm-sized, lab-on-a-chip diagnostic devices that utilize silicon photonics technology for the rapid at-home testing of bodily fluid samples. The medical technology company focuses on point-of-care diagnostics, creating single-use testing cartridges and reusable readers to detect sexually transmitted infections such as Chlamydia and Gonorrhea, alongside various respiratory viruses including SARS-CoV-2. Founded in 2018 by Jan-Willem Hoste, the enterprise originally launched as an independent technology spin-off from Ghent University, MyCartis, and the research institute imec. Operating with an estimated 10 to 50 employees, the growing organization has successfully raised approximately $16.6 million in total venture capital funding to advance its clinical trials and its future commercialization efforts. This vital financial backing includes major funding rounds supported by recognizable institutional investors such as Whitefund, imec.xpand, V-Bio Ventures, Capricorn Partners, RMM, and Saffelberg.
Antelope Dx has raised $10.7M across 1 funding round.
Antelope Dx has raised $10.7M in total across 1 funding round.
Antelope Dx has raised $10.7M in total across 1 funding round.
Antelope Dx's investors include White Fund.
Antelope Dx has raised $10.7M across 1 funding round. Most recently, it raised $10.7M Series B in September 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 15, 2020 | $10.7M Series B | White Fund | — | Announced |
